Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:06:26 EST Wed 17 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:AKTX - AKARI THERAPEUTICS PLC SPON ADR EACH REPR 2000 ORD - https://www.akaritx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AKTX - Q0.10.232·1.3226.80.2536-0.1574-38.33,399.57543,3580.30  0.34  0.22421.7225  0.264919:58:4709:2915 min RT 2¢

Recent Trades - Last 10 of 3358
Time ETExPriceChangeVolume
19:58:47Q0.255-0.1561,000
19:56:33Q0.255-0.1565
19:33:36Q0.255-0.15610
19:27:45Q0.257-0.154125
19:05:51Q0.258-0.15360
18:44:29Q0.258-0.153500
18:42:48Q0.258-0.15310
18:39:45Q0.258-0.1532
18:30:20Q0.258-0.1535
18:27:37Q0.258-0.15350

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-16 09:29U:AKTXNews ReleaseAkari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
2025-12-09 08:40U:AKTXNews ReleaseAkari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
2025-12-04 09:00U:AKTXNews ReleaseAkari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
2025-11-25 09:00U:AKTXNews ReleaseAkari Therapeutics Announces Release of the Next CEO Corner Segment
2025-11-18 08:35U:AKTXNews ReleaseAkari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
2025-11-10 08:30U:AKTXNews ReleaseAkari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
2025-11-04 09:25U:AKTXNews ReleaseAkari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
2025-10-30 08:35U:AKTXNews ReleaseAkari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
2025-10-22 09:05U:AKTXNews ReleaseAkari Therapeutics Announces Launch of CEO Corner Platform
2025-10-15 08:30U:AKTXNews ReleaseAkari Therapeutics Announces $2.5 Million Registered Direct Offering
2025-10-09 08:45U:AKTXNews ReleaseAkari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1
2025-10-03 09:30U:AKTXNews ReleaseAkari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
2025-09-24 08:45U:AKTXNews ReleaseAkari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
2025-09-17 08:45U:AKTXNews ReleaseAkari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
2025-09-05 06:45U:AKTXNews ReleaseAkari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-09-03 08:30U:AKTXNews ReleaseAkari Therapeutics to Participate in the Virtual Investor Closing Bell Series
2025-08-14 09:15U:AKTXNews ReleaseAkari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
2025-07-29 09:15U:AKTXNews ReleaseAkari Therapeutics Releases Virtual Investor "What This Means" Segment
2025-07-23 08:55U:AKTXNews ReleaseAkari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
2025-07-22 08:45U:AKTXNews ReleaseAkari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference